Adverse medical outcomes of early newborn screening programs for phenylketonuria

Pediatrics

Volumn 122, Issue 1, 2008, Pages 192-197

  Brosco, Jeffrey P ^a   Sanders, Lee M ^a   Seider, Michael I ^a   Dunn, Angela C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse outcomes; History; Newborn screening; Phenylketonuria

Indexed keywords

PHENYLALANINE;

DIAGNOSTIC ACCURACY; DIET RESTRICTION; EARLY DIAGNOSIS; FOLLOW UP; HEALTH PROGRAM; HUMAN; INFORMED CONSENT; INTERVIEW; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; NEWBORN SCREENING; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNITED STATES; DIAGNOSTIC ERROR; DIET THERAPY; LABORATORY DIAGNOSIS; NEWBORN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY;

DIAGNOSTIC ERRORS; DIET THERAPY; FALSE POSITIVE REACTIONS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLKETONURIAS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 48249134759     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-3027     Document Type: Review

References (46)

1. Alexander D. Prevention of mental retardation: four decades of research. Ment Retard Dev Disabil Res Rev. 1998;4(1):50-58
2. Brosco JP, Mattingly M, Sanders LM. Impact of specific medical interventions on reducing the prevalence of mental retardation. Arch Pediatr Adolesc Med. 2006;160(3):302-309
3. Thomason MJ, Lord J, Bain MD, et al. A systematic review of evidence for the appropriateness of neonatal screening programmes for inborn errors of metabolism. J Public Health Med. 1998;20(3):331-3434. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics. 2006;117(5): 1793-1799
4. Fost N. Bioethics and American children. Presented at: the President's Council on Bioethics meeting; December 8-9, 2005; Washington DC
5. Fost N. Ethics of pediatric medicine. In: McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB, eds. Oski's Pediatrics: Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:13-16
6. Howell RR. We need expanded newborn screening. Pediatrics. 2006;117(5):1800-1805
7. Brosco JP, Seider MI, Dunn AC. Universal newborn screening and adverse medical outcomes: a historical note. Ment Retard Dev Disabil Res Rev. 2006;12(4):262-269
8. Scriver CR. Whatever happened to PKU? Clin Biochem. 1995; 28(2):137-144
9. Hsia DY. Biochemical factors in mental retardation. Proc Annu Meet Am Psychopathol Assoc. 1967;56:28-44
10. Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register. Br Med J (Clin Res Ed). 1981;282(6277):1680- 1684
11. Rouse BM. Phenylalanine deficiency syndrome. J Pediatr. 1966;69(2):246-249
12. Texas Department of State Health Services. History of Newborn Screening Program. Available at: www.dshs.state.tx.us/newborn/faqs-nbs.shtm. Accessed December 12, 2006.
13. Schneider A, Garrard S. Persistent hyperphenylalaninemia. Presented at: annual meeting of the American Pediatrics Society; May 2-4, 1965; Philadelphia, PA
14. Hanley WB, Linsao L, Davidson W, Moes CA. Malnutrition with early treatment of phenylketonuria. Pediatr Res. 1970; 4(4):318-327
15. Berry HK, Sutherland BS, Umbarger B. Diagnosis and treatment: interpretation of results of blood screening studies for detection of phenylketonuria. Pediatrics. 1966;37(1):102-106
16. Hsia DY, Knox WE, Quinn KV, Paine RS. A one-year, controlled study of the effect of low-phenylalanine diet on phenylketonuria. Pediatrics. 1958;21(2):178-202
17. Woolf LI, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J. 1955;1(4905):57-64
18. Holt J, Allen R. Radiologic signs in the primary aminoacidurias. Ann Radiol (Paris). 1967;10(3):317-321
19. American Academy of Pediatrics, Committee on Nutrition. Nutritional management in hereditary metabolic disease. Pediatrics. 1967;40(2):289-304
20. Dodge PR, Mancall E, Crawford JD, Knapp J, Paine RS. Hypoglycemia complicating treatment of phenylketonuria with a phenylalanine-deficient diet: report of two cases. N Engl J Med. 1959;260(22):1104-1111
21. Moncrieff A, Wilkinson RH. Further experiences in the treatment of phenylketonuria. Br Med J. 1961;1(5228):763-767
22. Wilson KM, Clayton BE. Importance of choline during growth, with particular reference to synthetic diets in phenylketonuria. Arch Dis Child. 1962;37:565-577
23. Royston N, Parry T. Megaloblastic anaemia complicating dietary treatment of phenylketonuria in infancy. Arch Dis Child. 1962;37:430 - 435
24. Holt KS. Difficulties and dangers in the management of phenylketonuria. Acta Paediatr. 1963;52:417-423
25. Davison A. (H. Bickel, Discussion) Inborn errors of amino acid metabolism affecting myelination of the central nervous system. In: Hommes FA, Van Den Berg CJ, eds. Inborn Errors of Metabolism. London, United Kingdom: Academic Press; 1973:55-67
26. Holtzman NA. Dietary treatment of inborn errors of metabolism. Annu Rev Med. 1970;21:335-356
27. Allen RJ, Heffelfinger JC, Masotti RE, Tsau MU. Phenylalanine hydroxylase activity in newborn infants. Pediatrics. 1964;33(4): 512-525
28. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: phenylketonuria-screening and management, October 16-18, 2000. Pediatrics. 2001;108(4):972-982
29. Umbarger B, Berry HK, Sutherland BS. Advances in the management of patient with phenylketonuria. JAMA. 1965;193: 784-790
30. Berry HK, Sutherland BS, Umbarger B. Detection of phenylketonuria in newborn infants. JAMA. 1966;198(10):1114-1115
31. Bessman SP. Implications of the drive for screening. In: Anderson JA, Swaiman KF, eds. Phenylketonuria and Allied Metabolic Diseases. Washington, DC: US Government Printing Office; 1966:177-180
32. American Academy of Pediatrics, Committee on the Handicapped Child. Statement on treatment of phenylketonuria. Pediatrics. 1965;35(3):501-503
33. American Academy of Pediatrics, Committee on Fetus and Newborn. Screening of newborn infants for metabolic disease. Pediatrics. 1965;35(3):499-501
34. Berry HK, Wright S. Conference on treatment of phenylketonuria. J Pediatr. 1967;70(1):142-147
35. Anderson JA, Swaiman KF. Phenylketonuria and allied metabolic disorders: Proceedings of a conference held at Washington, DC, April 6-8, 1966. Washington, DC: US Government Printing Office, 1967.
36. Azen C, Koch R, Friedman E, Wenz E, Fishler K. Summary of findings from the United States Collaborative Study of Children Treated for Phenylketonuria. Eur J Pediatr. 1996; 155(suppl 1):S29-S32
37. Dietary treatment of phenylketonuria. Br Med J. 1968;4(5624): 135
38. Paul DB, Edelson PJ. The struggle over metabolic screening. In: de Chadarevian S, Kamminga H, eds. Molecularising Biology and Medicine: New Practices and Alliances, 1930s to 1970s (Studies in the History of Science, Technology and Medicine). Amsterdam, Netherlands: Harwood Academic Publishers; 1997:203-220
39. Rosenstock IM, Childs B, Simopoulos AP. Genetic Screening: A Study of the Knowledge and Attitudes of Physicians. Washington DC: National Academy of Sciences; 1975
40. Therrell BL, Hannon HW. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev. 2006;12(4):236-245
41. Marsden D, Levy H. Classification of PKU. In: Blau N, ed. PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn, Germany: SPS Verlagsgesellschaft; 2006:92-103
42. Bessman SP. Legislation and advances in medical knowledge: acceleration or inhibition? J Pediatr. 1966;69(2):334-338
43. Beutler E. Carrier screening for Gaucher disease: more harm than good? JAMA. 2007;298(11):1329-1331
44. Zuckerman S, Lahad A, Shmueli A, et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA. 2007;298(11):1281-1290
45. Wilson J, Jungner G. The Principles and Practice of Screening for Disease. Geneva, Switzerland: World Health Organization; 1968
46. Cooper JD. The role of government and legislation in management of problems in medicine. In: Anderson JA, Swaiman KF, eds. Phenylketonuria and Allied Metabolic Disorders: Proceedings of a conference held at Washington, DC, April 6-8, 1966. Washington, DC: US Government Printing Office; 1967: 168-176